Monjuvi

Chemical Nametafasitamab-cxix
Dosage FormInjection; Intravenous 200mg
Drug ClassMonoclonal antibodies
SystemBlood
CompanyMorphosys US Inc.
Approval Year2020

Indication

  • For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Monjuvi (tafasitamab-cxix) Prescribing Information. 2020Morphosys US Inc., Boston, MA